Biotechnology and the Future of Vaccines-From Novel Routes and Vectors to Safety, Efficacy, and Global Impact. [PDF]
Kuo TH, Chen YC.
europepmc +1 more source
A Rationally Engineered Spleen‐Tropic One‐Component Lipid‐mRNA Complex (OncoLRC) for Cancer Vaccines
OncoLRC, a one‐component lipid‐mRNA complex, enables efficient spleen‐targeted delivery at an exceptionally low lipid‐to‐mRNA mass ratio (1.5:1), robustly activates immune responses, inhibits tumor growth, and synergizes with checkpoint blockade, presenting a next‐generation platform for mRNA vaccines.
Qimeng Yin +4 more
wiley +1 more source
Editorial: Epitope Discovery and Synthetic Vaccine Design
Clarisa Beatriz Palatnik-de-Sousa +4 more
doaj +1 more source
Synthetic DNA co-immunization with vaccine-aligned common consensus nucleoprotein and hemagglutinin protects mice against lethal influenza infection with a single immunization. [PDF]
Gary EN +14 more
europepmc +1 more source
Polymeric carriers provide versatile platforms for nucleic acid delivery. This review introduces a novel perspective inspired by protein structural organization to explore structure–function relationships of polymeric carriers, highlighting requirements of different nucleic acid payloads.
Hanieh Moradian +3 more
wiley +1 more source
Application progress and biosafety challenges of gene editing and synthetic biotechnology in diagnosis, treatment and prevention of infectious diseases. [PDF]
Gao Z +12 more
europepmc +1 more source
Targeting Endothelial KDM5A to Attenuate Aging and Ameliorate Age‐Associated Metabolic Abnormalities
This study identifies endothelial KDM5A as a key regulator of aging. KDM5A deficiency accelerates aging by enhancing H3K4me3‐mediated FABP4 expression, disrupting fatty acid metabolism, and promoting multi‐organ senescence. KDM5A restoration or FABP4 inhibition reverses these adverse effects and extends lifespan, positioning the KDM5A/FABP4 axis as a ...
Rifeng Gao +21 more
wiley +1 more source
From bark to bench: innovations in QS-21 adjuvant characterization and manufacturing. [PDF]
Talukdar P +6 more
europepmc +1 more source
The development of a novel engineered strain of Lactiplantibacillus plantarum (Lp) is reported that can produce bacterial extracellular vesicles (BEVs) at >60‐fold higher yields than the unmodified parental strain. These Lp BEVs retain therapeutic bioactivity as validated in a mouse model of dextran sodium sulfate‐induced colitis.
Nicholas H Pirolli +16 more
wiley +1 more source
DNA Vaccines in the Post-mRNA Era: Engineering, Applications, and Emerging Innovations. [PDF]
Neeli P +4 more
europepmc +1 more source

